225 related articles for article (PubMed ID: 18158351)
21. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation.
Yoshida T; Yamagishi S; Matsui T; Nakamura K; Ueno T; Takeuchi M; Sata M
J Int Med Res; 2008; 36(2):237-43. PubMed ID: 18380932
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
Schupp M; Janke J; Clasen R; Unger T; Kintscher U
Circulation; 2004 May; 109(17):2054-7. PubMed ID: 15117841
[TBL] [Abstract][Full Text] [Related]
23. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide-1(9-36) inhibits chemokine-induced migration of human CD4-positive lymphocytes.
Liberman A; Esser M; Marx N; Burgmaier M
PLoS One; 2013; 8(3):e58445. PubMed ID: 23469279
[TBL] [Abstract][Full Text] [Related]
25. Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma.
Yao Y; Zou R; Liu X; Jiang J; Huang Q; He Y; Li M; Wang S; Zhou J; Ma D; Xu G
J Huazhong Univ Sci Technolog Med Sci; 2008 Oct; 28(5):543-8. PubMed ID: 18846335
[TBL] [Abstract][Full Text] [Related]
26. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes.
Marx N; Burgmaier M; Heinz P; Ostertag M; Hausauer A; Bach H; Durst R; Hombach V; Walcher D
Cell Mol Life Sci; 2010 Oct; 67(20):3549-55. PubMed ID: 20495843
[TBL] [Abstract][Full Text] [Related]
28. Telmisartan modulates mitochondrial function in vascular smooth muscle cells.
Takeuchi K; Yamamoto K; Ohishi M; Takeshita H; Hongyo K; Kawai T; Takeda M; Kamide K; Kurtz TW; Rakugi H
Hypertens Res; 2013 May; 36(5):433-9. PubMed ID: 23254392
[TBL] [Abstract][Full Text] [Related]
29. Long-term amelioration of telmisartan on metabolic syndrome-related molecules in stroke-resistant spontaneously hypertensive rat after transient middle cerebral artery occlusion.
Deguchi K; Kurata T; Fukui Y; Liu W; Yun Z; Omote Y; Sato K; Kono S; Hishikawa N; Yamashita T; Abe K
J Stroke Cerebrovasc Dis; 2014; 23(10):2646-2653. PubMed ID: 25307428
[TBL] [Abstract][Full Text] [Related]
30. Ivabradine reduces chemokine-induced CD4-positive lymphocyte migration.
Walcher T; Bernhardt P; Vasic D; Bach H; Durst R; Rottbauer W; Walcher D
Mediators Inflamm; 2010; 2010():751313. PubMed ID: 21188276
[TBL] [Abstract][Full Text] [Related]
31. Beyond the classic angiotensin-receptor-blocker profile.
Kurtz TW
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S19-26. PubMed ID: 18580862
[TBL] [Abstract][Full Text] [Related]
32. Different effects of telmisartan and valsartan on human aortic vascular smooth muscle cell proliferation.
Wang L; Zhao L; Zhang D; Chen JZ; Xue JL
Chin Med J (Engl); 2012 Jun; 125(12):2200-4. PubMed ID: 22884153
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?
Benson SC; Iguchi R; Ho CI; Yamamoto K; Kurtz TW
J Hypertens; 2008 May; 26(5):973-80. PubMed ID: 18398340
[TBL] [Abstract][Full Text] [Related]
34. Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPARγ activation.
Chen HY; Xu Z; Chen LF; Wang W; Fang Q; Yan XW
J Cardiovasc Pharmacol; 2012 Jun; 59(6):570-5. PubMed ID: 22392065
[TBL] [Abstract][Full Text] [Related]
35. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action.
Ishiguro H; Ishiguro Y; Kubota Y; Uemura H
Prostate; 2007 Jun; 67(9):924-32. PubMed ID: 17440964
[TBL] [Abstract][Full Text] [Related]
36. Deletion of angiotensin II type I receptor reduces hepatic steatosis.
Nabeshima Y; Tazuma S; Kanno K; Hyogo H; Chayama K
J Hepatol; 2009 Jun; 50(6):1226-35. PubMed ID: 19395110
[TBL] [Abstract][Full Text] [Related]
37. Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice.
Shiota A; Shimabukuro M; Fukuda D; Soeki T; Sato H; Uematsu E; Hirata Y; Kurobe H; Maeda N; Sakaue H; Masuzaki H; Shimomura I; Sata M
Cardiovasc Diabetol; 2012 Nov; 11():139. PubMed ID: 23137106
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.
Janke J; Schupp M; Engeli S; Gorzelniak K; Boschmann M; Sauma L; Nystrom FH; Jordan J; Luft FC; Sharma AM
J Hypertens; 2006 Sep; 24(9):1809-16. PubMed ID: 16915030
[TBL] [Abstract][Full Text] [Related]
39. The effect of Telmisartan on collagen biosynthesis depends on the status of estrogen activation in breast cancer cells.
Kociecka B; Surazynski A; Miltyk W; Palka J
Eur J Pharmacol; 2010 Feb; 628(1-3):51-6. PubMed ID: 19945454
[TBL] [Abstract][Full Text] [Related]
40. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
